Retatrutide clinical trial doses: what the studies actually used

Last updated 2026-07-25

What dose did the retatrutide clinical trial actually use?

The phase 2 obesity trial tested retatrutide as a once-weekly subcutaneous injection across several dose arms, with a slow up-titration schedule and a top studied dose of 12 mg. At 48 weeks, the 12 mg group showed a mean weight reduction of 24.2 percent, compared with 2.1 percent in the placebo group ^[1]. That trial is registered on ClinicalTrials.gov as NCT04881760, under the drug's development code LY3437943 ^[2]. This is the number you'll see quoted everywhere: 24.2 percent. It's real, it's from a peer-reviewed New England Journal of Medicine paper, and it's the headline result that made retatrutide famous before most people had ever heard the word. But a single trial result isn't the same thing as a dose that's safe or appropriate for any given person outside that study. Trial participants were screened, monitored, and titrated under controlled conditions. Nobody buying vials off a gray-market site is getting any of that. It's also worth being precise about what "12 mg" means in context. The trial used multiple lower dose arms below 12 mg, and participants were titrated upward gradually rather than starting at the top dose. The published trial reports the specific titration schedule and dose arms tested ^[1], which is the only source anyone should be citing for what the drug was actually given at, and how.

How does the trial dosing schedule work, and why does titration matter?

Trial dosing followed a gradual up-titration model rather than jumping straight to the target maintenance dose. This is standard practice for injectable incretin drugs (the same approach is used with approved GLP-1 and GIP drugs) because starting high tends to cause more gastrointestinal side effects: nausea, vomiting, and diarrhea are the dose-limiting problems with this whole drug class. The point of titration in a trial isn't cosmetic. It lets researchers separate a tolerable, gradually-escalated regimen from one that would cause too many people to drop out from side effects. The dosing schedule tested in the phase 2 trial is documented in the trial's published methods and its ClinicalTrials.gov record ^{[1] [2]}, and it reflects a specific, monitored protocol designed by trial investigators for a controlled patient population. None of that transfers to unsupervised, self-directed dosing. A titration schedule that worked in a monitored 48-week trial with regular clinical check-ins is not a home protocol. There's no clinician anywhere who can legally write a prescription for retatrutide dosing outside a registered trial, because the drug has no FDA-approved status for any use ^[3].

Is retatrutide FDA-approved at any dose?

No. A search of Drugs@FDA, the FDA's own database of approved drug products, for the generic name retatrutide returns no approved product at any dose, in any formulation ^[3]. That means there is no FDA-reviewed prescribing information, no approved label, no approved dosing regimen, and no lawful prescription pathway for retatrutide in the United States, for weight loss, diabetes, or anything else. This is a common point of confusion because trial results get reported in the media with specific numbers (24.2 percent weight loss, 12 mg dose) that sound like settled facts about a marketed drug. They're not. They're results from a controlled phase 2 study, and the drug remains investigational. Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an FDA-approved application, full stop ^[4]. That's the entire legal basis for why retatrutide isn't available at a pharmacy at any dose.

Can a compounding pharmacy legally make retatrutide at any dose?

No, and this is worth explaining clearly because a lot of vendor marketing implies otherwise. Section 503A of the FD&C Act allows pharmacies to compound drugs from bulk substances, but only through a strict three-step cascade: the substance must comply with an applicable USP or NF monograph if one exists; if no monograph exists, it must be a component of an FDA-approved drug; only if neither of those applies can it come from the FDA's 503A Bulks List ^[5]. Retatrutide fails all three tests. There's no USP or NF monograph for it. It isn't a component of any FDA-approved drug, since no retatrutide product has been approved ^[3]. And it isn't on the 503A Bulks List, which contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[6]. No peptide is on that list, and retatrutide has never been nominated for it, unlike substances like BPC-157, KPV, and TB-500, which the FDA's Pharmacy Compounding Advisory Committee actually reviewed at a July 2026 meeting ^[7]. Even a favorable advisory committee vote wouldn't create a compounding pathway on its own; adding anything to the Bulks List requires full notice-and-comment rulemaking ^[7]. On top of the ingredient cascade, 503A separately requires that any bulk substance used in compounding come from a facility registered under section 510 of the FD&C Act and ship with a valid certificate of analysis ^[5]. Research-use-only material from an unregistered supplier fails this requirement regardless of anything else about the ingredient itself. There is, in short, no legal way for a US compounding pharmacy to dispense retatrutide at any dose, trial-tested or otherwise. For more on this specific legal mechanism, see retatrutide peptide buy.

What about vendor sites selling retatrutide as 'research use only'?

A research-use-only label on a vendor's product page doesn't change how FDA evaluates what that product actually is. FDA's own regulation on labelling states that a product's "intended use" is determined by "labeling claims, advertising matter, or oral or written statements by [the seller] or their representatives," not by a disclaimer buried in the fine print ^[8]. In a March 2026 warning letter to a peptide seller, FDA made this point directly. The agency wrote that despite a research-use-only disclaimer, "evidence from the company's website established that its products were intended to be drugs for human use," and the letter specifically named retatrutide among the products marketed on that site ^[9]. If a site describes retatrutide's fat-loss effects, dosing protocols, or trial results in a way that reads as a pitch to human customers, FDA can and does treat that as drug marketing, disclaimer or not. This matters for anyone tempted to treat a "research chemical" listing as a loophole. It isn't one. The seller's marketing language is the thing that establishes intended use, and that's true regardless of what the label says ^{[8] [9]}.

What other retatrutide trials exist beyond the phase 2 obesity study?

The phase 2 obesity trial (NCT04881760) is the most widely cited, but it isn't the only registered study. Retatrutide has also been tested in registered type 2 diabetes trials, meaning the evidence base spans more than one indication ^[2]. The drug has since moved into later-phase trials as well, with at least two additional registrations publicly listed on ClinicalTrials.gov: NCT05929066 and NCT05882045 ^{[10] [3]}. Each of those records lists its own enrollment criteria, comparator arms, and endpoints, which is the right place to look if you want specifics on what a given trial is actually testing, rather than relying on secondhand summaries. None of these later trials have produced an FDA approval, and none change the legal status described above. A drug can sit in phase 3 trials for years, sometimes with strong results, and still have zero lawful path to a pharmacy shelf until the FDA approves a specific application.

How does retatrutide's mechanism differ from the trial doses of semaglutide and tirzepatide?

Retatrutide is a triple agonist, meaning it activates three separate receptors: GIP, GLP-1, and glucagon. That's mechanistically distinct from semaglutide, which acts only on the GLP-1 receptor, and tirzepatide, which acts on GIP and GLP-1 but not the glucagon receptor ^[1]. The added glucagon receptor activity is the mechanistic reason researchers have been interested in retatrutide specifically, since glucagon receptor agonism is linked to increased energy expenditure in addition to appetite suppression. | Drug | Receptors targeted | FDA status | Trial/label top dose |

If retatrutide isn't approved, what are lawful options right now?

If you're looking at retatrutide because of the 24.2 percent weight loss headline, it's worth knowing that two incretin-based drugs with FDA approval and published safety data already exist and are prescribable today: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) ^[11]. A newer oral option, orforglipron, was approved as Foundayo under NDA 220934 in six strengths ranging from 0.8 mg to 17.2 mg, giving patients an oral incretin option where previously only injectables existed ^[12]. Any of these requires a conversation with a prescribing clinician who can weigh your health history, current medications, and goals, something no gray-market vial can replace. NIDDK, the federal government's diabetes and digestive disease research institute, publishes general guidance on evidence-based weight management approaches that's a reasonable neutral starting point if you're comparing options ^[13]. If you want to understand how trial dosing compares across the incretin class, or how titration schedules are typically structured, see retatrutide dosage chart and retatrutide dosage calculator. Neither of those resources is a substitute for a prescription; they exist to help you understand the trial data, not to guide self-administration.

What does FDA's personal importation policy mean for ordering retatrutide from overseas?

Some people consider ordering unapproved drugs from foreign pharmacies or research suppliers, assuming personal use puts them outside FDA's reach. FDA publishes a specific policy page on personal importation of unapproved drugs, and it's the operative guidance for anyone considering this route . The short version: FDA generally does not permit importation of unapproved drugs for personal use, and the agency retains discretion over enforcement, meaning packages can be detained or refused entirely regardless of quantity or intent. Retatrutide is not approved for any indication in the US ^[3], so it falls squarely under this restriction. There's also a quality problem layered on top of the legal one: an overseas or research-use-only supplier isn't required to meet US manufacturing, purity, or sterility standards, so even if a package clears customs, you have no reliable way to verify what's actually in the vial or at what concentration.

Why can't a doctor just write a prescription for retatrutide off-label?

Off-label prescribing lets doctors prescribe an *approved* drug for a use not listed on its label. It does not let doctors prescribe a drug that has never been approved for *any* use. Retatrutide has zero FDA-approved indications ^[3], so there's no approved product to prescribe off-label in the first place. This is a different legal situation from, say, a doctor prescribing an approved diabetes drug for weight loss before it had a weight-loss-specific approval. The only lawful way a person can currently receive retatrutide is by being enrolled as a participant in one of its registered clinical trials, such as NCT04881760, NCT05929066, or NCT05882045 ^{[2] [10] [3]}, where dosing is administered and monitored by the study's investigators under an FDA-reviewed protocol. Outside of that structure, there is no prescription pathway, compounded or otherwise.

Frequently asked questions

What was the highest dose of retatrutide tested in clinical trials?

The phase 2 obesity trial tested doses up to 12 mg, given as a once-weekly subcutaneous injection with gradual up-titration. That dose group showed a mean weight reduction of 24.2 percent at 48 weeks, versus 2.1 percent for placebo. This is documented in the New England Journal of Medicine publication and the trial's ClinicalTrials.gov registration, NCT04881760.

Is retatrutide approved by the FDA at any dose?

No. A search of Drugs@FDA, the FDA's database of approved drug products, returns no approved product under the name retatrutide, at any dose or for any indication. It remains an investigational drug studied only in registered clinical trials, with no FDA-reviewed label or dosing information available to prescribers or patients.

Can a compounding pharmacy make retatrutide using the trial dose?

No. Section 503A requires a bulk substance to satisfy a USP/NF monograph, be a component of an approved drug, or appear on the 503A Bulks List. Retatrutide meets none of these, and the six-substance Bulks List contains no peptides. Even if a pharmacy wanted to replicate the trial's 12 mg dose, there is no lawful compounding pathway for the ingredient itself.

How much weight loss did the retatrutide trial show?

In the phase 2 obesity trial, the 12 mg dose group achieved a mean weight reduction of 24.2 percent at 48 weeks, compared with 2.1 percent in the placebo group. That result comes from a peer-reviewed paper in the New England Journal of Medicine and the study's ClinicalTrials.gov record, NCT04881760.

What receptors does retatrutide activate compared to semaglutide and tirzepatide?

Retatrutide is a triple agonist, activating GIP, GLP-1, and glucagon receptors. Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GIP and GLP-1 but not glucagon. This added glucagon receptor activity is the mechanistic feature researchers point to when explaining retatrutide's trial results relative to the other two.

Does a research-use-only label make retatrutide sales legal?

No. FDA regulation 21 CFR 201.128 states that intended use is established by labeling claims and advertising, not disclaimers. In a March 2026 warning letter, FDA found that a seller's website established retatrutide products were intended for human drug use despite a research-use-only label, and cited that seller specifically.

Are there other retatrutide trials besides the phase 2 obesity study?

Yes. Retatrutide has been studied in registered type 2 diabetes trials as well as obesity, and has advanced into later-phase trials, including registrations listed as NCT05929066 and NCT05882045 on ClinicalTrials.gov. Each record lists its own enrollment criteria and endpoints for anyone wanting the primary source rather than secondhand summaries.

Can I legally import retatrutide from another country for personal use?

FDA's personal importation policy generally does not permit bringing in unapproved drugs for personal use, and the agency has enforcement discretion regardless of quantity. Since retatrutide has no US approval for any indication, it falls under this restriction, and packages can be detained. Overseas suppliers also aren't held to US manufacturing or purity standards.

Was retatrutide ever nominated for the FDA's compounding bulk substances list?

No. FDA's Pharmacy Compounding Advisory Committee met in July 2026 to review seven other peptides, including BPC-157, KPV, TB-500, and semax, for possible inclusion on the 503A Bulks List. Retatrutide was not among them and has never been nominated for that list, according to the Federal Register docket for that meeting.

Can a doctor prescribe retatrutide off-label since it showed strong trial results?

No. Off-label prescribing applies only to drugs that already have at least one FDA approval. Retatrutide has zero approved indications, so there is no approved product to prescribe off-label. The only lawful way to receive retatrutide is enrollment in one of its active registered clinical trials under investigator supervision.

What FDA-approved alternatives exist while retatrutide remains investigational?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved incretin drugs with published safety data. Orforglipron, an oral GLP-1 agonist, was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg. All three require a prescribing clinician's evaluation rather than self-directed sourcing.

Why does the trial dosing schedule use titration instead of starting at 12 mg?

Gradual up-titration reduces gastrointestinal side effects like nausea and vomiting, which are the main tolerability problems across the GLP-1/GIP/glucagon drug class. The phase 2 trial's published methods and ClinicalTrials.gov record describe the specific titration schedule used, which was designed and monitored by trial investigators, not something reproducible safely without clinical supervision.

Sources

1. Jastreboff AM et al., New England Journal of Medicine, 2023: Phase 2 trial: 12 mg dose produced 24.2% mean weight loss at 48 weeks vs 2.1% placebo; triple agonist mechanism (GIP, GLP-1, glucagon); titration schedule and dose arms.
2. ClinicalTrials.gov NCT04881760: Registration record for the phase 2 obesity trial (LY3437943/retatrutide), dose arms, route, and type 2 diabetes trial existence.
3. Drugs@FDA, FDA-approved drug products database: A search for retatrutide returns no approved product at any dose or indication.
4. 21 U.S.C. 355: A new drug cannot be introduced into interstate commerce without an FDA-approved application.
5. 21 U.S.C. 353a(b)(1)(A)(i): 503A ingredient cascade: monograph compliance, then component of approved drug, then Bulks List, in that order.
6. 21 CFR 216.23, eCFR current through 2026-07-08: The complete 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not among them.
7. Federal Register, Docket FDA-2025-N-6895, published 16 April 2026: July 2026 Pharmacy Compounding Advisory Committee meeting reviewed seven other peptides, not retatrutide; advisory votes are non-binding and require notice-and-comment rulemaking to change the Bulks List.
8. 21 CFR 201.128: Intended use is established by labeling claims, advertising, or seller statements, not by a disclaimer.
9. ClinicalTrials.gov NCT05929066: Registration record for a later-phase retatrutide trial listing enrollment criteria, comparators, and endpoints.
10. ClinicalTrials.gov NCT05882045: Second independent later-phase retatrutide trial registration record.
11. Drugs@FDA, NDA 220934: Orforglipron approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg.
12. NIDDK, Weight Management: Federal guidance on evidence-based weight management as a neutral reference point.
13. FDA, Personal Importation: FDA policy on personal importation of unapproved drugs and enforcement discretion.